Dr Nigel Whittle
With a biochemistry degree from Oxford and a PhD in the discovery of oncogenes, Nigel started work in the embryonic biotechnology industry to help bring some amazing discoveries into the clinic, first at Genentech Inc in the US, and then at Celltech and later Cantab Pharmaceuticals in the UK. He later set up his own successful life science consultancy before joining Plextek to build their medical and healthcare business, working with a range of talented people in innovative medical device organisations.
Latest articles
R&D spending in the UK pharmaceutical sector has jumped 6.9% annually
Analysis of the latest ONS data by R&D tax relief specialists Catax shows that R&D spending in the UK pharmaceutical sector has jumped 6.9%...
New COVID-19 screening technology could test large groups with rapid response
The Technology Partnership Plc (TTP) is developing a new pooled screening technology for COVID-19 that can be used for the screening of large groups,...
Distribution and scaling up a Covid-19 vaccine
The development and distribution of a safe and effective vaccine is widely seen as the best resolution to the COVID-19 pandemic, and the most...
Popular articles
New Normal, New Thinking: Life Post COVID-19
New thinking will be required to adapt to the new normal life post COVID-19. I hate to start this article on a negative note, but...
Nasal spray to protect against COVID-19 is ready for use in humans
A nasal spray to provide protection against the COVID-19 virus has been formulated by researchers at the University of Birmingham, UK, using compounds already...
Distribution and scaling up a Covid-19 vaccine
The development and distribution of a safe and effective vaccine is widely seen as the best resolution to the COVID-19 pandemic, and the most...
New COVID-19 screening technology could test large groups with rapid response
The Technology Partnership Plc (TTP) is developing a new pooled screening technology for COVID-19 that can be used for the screening of large groups,...
NICE recommends BRAFTOVI®▼(encorafenib) for previously treated adults with metastatic colorectal cancer
The National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Determination (FAD) recommending BRAFTOVI®▼(encorafenib) plus cetuximab, within its marketing authorisation, as...